• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For March 27, 2024

    3/27/24 5:02:44 AM ET
    $AGAE
    $ALT
    $AMS
    $AQMS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGAE alert in real time by email

    Companies Reporting Before The Bell

    • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.

    • REE Automotive (NASDAQ:REE) is estimated to report quarterly loss at $2.38 per share on revenue of $1.35 million.

    • Precision BioSciences (NASDAQ:DTIL) is projected to report quarterly loss at $2.05 per share on revenue of $12.48 million.

    • Edap TMS (NASDAQ:EDAP) is expected to report quarterly loss at $0.05 per share on revenue of $19.66 million.

    • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is expected to report earnings for its fourth quarter.

    • Cellectar Biosciences (NASDAQ:CLRB) is likely to report earnings for its fourth quarter.

    • Gamida Cell (NASDAQ:GMDA) is projected to report quarterly loss at $0.15 per share on revenue of $1.06 million.

    • PDS Biotechnology (NASDAQ:PDSB) is likely to report earnings for its fourth quarter.

    • Altimmune (NASDAQ:ALT) is projected to report earnings for its fourth quarter.

    • Syros Pharmaceuticals (NASDAQ:SYRS) is estimated to report quarterly loss at $1.14 per share on revenue of $2.00 million.

    • Lands' End (NASDAQ:LE) is expected to report quarterly earnings at $0.21 per share on revenue of $502.71 million.

    • Cintas (NASDAQ:CTAS) is projected to report quarterly earnings at $3.58 per share on revenue of $2.39 billion.

    • GlycoMimetics (NASDAQ:GLYC) is projected to report earnings for its fourth quarter.

    • Sonida Senior Living (NYSE:SNDA) is projected to report earnings for its fourth quarter.

    • UniFirst (NYSE:UNF) is projected to report quarterly earnings at $1.42 per share on revenue of $587.84 million.

    Companies Reporting After The Bell

    • Creative Media (NASDAQ:CMCT) is estimated to report quarterly loss at $0.48 per share on revenue of $30.20 million.

    • Draganfly (NASDAQ:DPRO) is likely to report earnings for its fourth quarter.

    • VNET Gr (NASDAQ:VNET) is projected to report quarterly loss at $0.18 per share on revenue of $279.03 million.

    • RH (NYSE:RH) is estimated to report quarterly earnings at $1.67 per share on revenue of $777.48 million.

    • American Shared Hospital (AMEX:AMS) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.19 million.

    • Cosan (NYSE:CSAN) is likely to report quarterly earnings at $0.16 per share on revenue of $7.45 billion.

    • Greenidge Generation Hldg (NASDAQ:GREE) is estimated to report quarterly earnings at $0.25 per share on revenue of $26.70 million.

    • Gaia (NASDAQ:GAIA) is estimated to report quarterly loss at $0.02 per share on revenue of $21.00 million.

    • Allied Gaming (NASDAQ:AGAE) is projected to report earnings for its fourth quarter.

    • Jefferies Financial Gr (NYSE:JEF) is likely to report quarterly earnings at $0.75 per share on revenue of $1.52 billion.

    • LogicMark (NASDAQ:LGMK) is expected to report quarterly loss at $1.73 per share on revenue of $2.28 million.

    • H.B. Fuller (NYSE:FUL) is projected to report quarterly earnings at $0.64 per share on revenue of $825.03 million.

    • Sprinklr (NYSE:CXM) is likely to report quarterly earnings at $0.09 per share on revenue of $188.73 million.

    • Dynagas LNG Partners (NYSE:DLNG) is expected to report quarterly earnings at $0.30 per share on revenue of $38.21 million.

    • Durect (NASDAQ:DRRX) is estimated to report quarterly loss at $0.33 per share on revenue of $2.48 million.

    • Celcuity (NASDAQ:CELC) is expected to report earnings for its fourth quarter.

    • BioCardia (NASDAQ:BCDA) is estimated to report quarterly loss at $0.11 per share on revenue of $90 thousand.

    • Consolidated Water Co (NASDAQ:CWCO) is likely to report quarterly earnings at $0.44 per share on revenue of $45.25 million.

    • Silver Spike Investment (NASDAQ:SSIC) is projected to report quarterly earnings at $0.27 per share on revenue of $3.37 million.

    • Urban-gro (NASDAQ:UGRO) is estimated to report quarterly loss at $0.13 per share on revenue of $28.94 million.

    • PLBY Group (NASDAQ:PLBY) is estimated to report quarterly loss at $0.14 per share on revenue of $32.27 million.

    • Usio (NASDAQ:USIO) is projected to report quarterly earnings at $0.00 per share on revenue of $20.43 million.

    • Franklin Covey (NYSE:FC) is estimated to report quarterly earnings at $0.05 per share on revenue of $62.02 million.

    • Super League Enterprise (NASDAQ:SLE) is estimated to report quarterly loss at $1.20 per share on revenue of $9.30 million.

    • Spectral AI (NASDAQ:MDAI) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million.

    • Strata Skin Sciences (NASDAQ:SSKN) is estimated to report quarterly loss at $0.02 per share on revenue of $10.01 million.

    • Verint Systems (NASDAQ:VRNT) is estimated to report quarterly earnings at $0.97 per share on revenue of $263.12 million.

    • Eastside Distilling (NASDAQ:EAST) is projected to report quarterly loss at $0.90 per share on revenue of $3.68 million.

    • Braze (NASDAQ:BRZE) is likely to report quarterly loss at $0.05 per share on revenue of $124.86 million.

    • Oncology Institute (NASDAQ:TOI) is expected to report quarterly loss at $0.11 per share on revenue of $82.04 million.

    • Aqua Metals (NASDAQ:AQMS) is expected to report quarterly loss at $0.05 per share on revenue of $50 thousand.

    • Kingstone Companies (NASDAQ:KINS) is estimated to report quarterly loss at $0.08 per share on revenue of $29.65 million.

    • MillerKnoll (NASDAQ:MLKN) is projected to report quarterly earnings at $0.44 per share on revenue of $909.50 million.

    • Rumble (NASDAQ:RUM) is likely to report quarterly loss at $0.22 per share on revenue of $28.13 million.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGAE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGAE
    $ALT
    $AMS
    $AQMS

    CompanyDatePrice TargetRatingAnalyst
    MillerKnoll Inc.
    $MLKN
    2/10/2026Outperform
    William Blair
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Cintas Corporation
    $CTAS
    1/14/2026$245.00Equal Weight → Overweight
    Wells Fargo
    Sonida Senior Living Inc.
    $SNDA
    1/9/2026Neutral
    Robert W. Baird
    Braze Inc.
    $BRZE
    12/17/2025$45.00Buy
    BTIG Research
    Celcuity Inc.
    $CELC
    12/12/2025$126.00Overweight
    Wells Fargo
    RH
    $RH
    12/12/2025$165.00Buy → Hold
    Stifel
    RH
    $RH
    12/12/2025$220.00 → $185.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $AGAE
    $ALT
    $AMS
    $AQMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Ross William Masters sold $227,157 worth of shares (1,128 units at $201.38), decreasing direct ownership by 23% to 3,849 units (SEC Form 4)

    4 - UNIFIRST CORP (0000717954) (Issuer)

    2/10/26 3:06:47 PM ET
    $UNF
    Other Consumer Services
    Consumer Discretionary

    President & CEO Read Rory P bought $152 worth of shares (20 units at $7.60) and sold $996,726 worth of shares (165,858 units at $6.01), decreasing direct ownership by 10% to 1,506,270 units (SEC Form 4)

    4 - Sprinklr, Inc. (0001569345) (Issuer)

    2/9/26 5:00:05 PM ET
    $CXM
    Computer Software: Prepackaged Software
    Technology

    Large owner Tether Global Investments Fund, S.I.C.A.F., S.A. bought $4,220,298 worth of shares (777,012 units at $5.43) (SEC Form 4)

    4 - Rumble Inc. (0001830081) (Issuer)

    2/6/26 8:42:27 PM ET
    $RUM
    Computer Software: Programming Data Processing
    Technology

    $AGAE
    $ALT
    $AMS
    $AQMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Read Rory P bought $152 worth of shares (20 units at $7.60) and sold $996,726 worth of shares (165,858 units at $6.01), decreasing direct ownership by 10% to 1,506,270 units (SEC Form 4)

    4 - Sprinklr, Inc. (0001569345) (Issuer)

    2/9/26 5:00:05 PM ET
    $CXM
    Computer Software: Prepackaged Software
    Technology

    Large owner Tether Global Investments Fund, S.I.C.A.F., S.A. bought $4,220,298 worth of shares (777,012 units at $5.43) (SEC Form 4)

    4 - Rumble Inc. (0001830081) (Issuer)

    2/6/26 8:42:27 PM ET
    $RUM
    Computer Software: Programming Data Processing
    Technology

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGAE
    $ALT
    $AMS
    $AQMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on MillerKnoll

    William Blair initiated coverage of MillerKnoll with a rating of Outperform

    2/10/26 8:01:31 AM ET
    $MLKN
    Office Equipment/Supplies/Services
    Consumer Discretionary

    Barclays initiated coverage on Altimmune with a new price target

    Barclays initiated coverage of Altimmune with a rating of Overweight and set a new price target of $20.00

    1/28/26 7:15:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cintas upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cintas from Equal Weight to Overweight and set a new price target of $245.00

    1/14/26 8:20:54 AM ET
    $CTAS
    Garments and Clothing
    Industrials

    $AGAE
    $ALT
    $AMS
    $AQMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aqua Metals Enters Into a Term Sheet to Acquire Leading Energy Storage Company Lion Energy

    Combined Entity Would Integrate Energy Storage Products, Proprietary Energy Management Software, Recycling, and Battery Materials into a Single Platform Lion Energy is a Revenue-Generating Business, Enhanced by Proprietary Software and Positioned to Participate in Expanding Energy & Virtual Power Plant Markets RENO, Nev. and AMERICAN FORK, Utah, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ:AQMS), a pioneer in battery metals recycling and refining, today announced that it has entered into a term sheet to acquire Lion Energy, LLC, a U.S.-based provider of commercial, residential, and distributed energy storage systems, consumer power solutions, and proprietary energy managem

    2/11/26 9:00:00 AM ET
    $AQMS
    Metal Fabrications
    Industrials

    Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

    – U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – Institutional Review Board (IRB) process is underway at multiple world-class DMD clinical trial sites – – PBGENE-DMD is an in vivo gene editing investigational product designed to correct the underlying genetic cause of DMD through a novel one-time gene editing therapy – – Company plans to host a virtual event in March after the Muscular Dystrophy Association conference to discuss PBGENE-DMD and the FUNCTION-DMD clinical study with participation from key opinion leaders including patient advo

    2/11/26 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

    SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to FDA under its Q-Submission program for the approval of its Helix Transendocardial Delivery Catheter ("Helix") for intramyocardial therapeutic and diagnostic agent delivery.    The data supporting safety and effectiveness for the Helix Pre-Submission is from fifteen well-controlled clinical trials of cell and gene therapy delivery to the heart using Helix, where patients were enrolled in three primary cardiac clinical indications. The Helix

    2/10/26 9:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGAE
    $ALT
    $AMS
    $AQMS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Spectral AI Inc.

    SCHEDULE 13G - Spectral AI, Inc. (0001833498) (Subject)

    2/11/26 2:31:32 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Precision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    2/11/26 7:15:16 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Spectral AI Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Spectral AI, Inc. (0001833498) (Filer)

    2/10/26 4:01:26 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $AGAE
    $ALT
    $AMS
    $AQMS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $AGAE
    $ALT
    $AMS
    $AQMS
    Leadership Updates

    Live Leadership Updates

    View All

    Spectral AI Names Vincent S. Capone as Chief Executive Officer

    DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set

    2/10/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Paychex Expands Board of Directors, Appoints New Member

    Experienced executive, J. Michael Hansen, appointed to Paychex Board of Directors Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management (HCM) company, announced today that the company's Board of Directors has voted to expand to 11 members from 10 members. The Board has also appointed J. Michael Hansen to fill the new position as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119850035/en/ Mr. Hansen brings deep financial expertise, having served as Executive Vice President & Chief Financial Officer (CFO) of Cintas Corporation (NASDAQ:CTAS) for more than 10 years. Upon his retirem

    1/20/26 8:30:00 AM ET
    $CTAS
    $PAYX
    Garments and Clothing
    Industrials
    Diversified Commercial Services

    MillerKnoll Appoints Former J. Jill CEO Claire Spofford to Board of Directors

    ZEELAND, Mich., Jan. 16, 2026 /PRNewswire/ -- MillerKnoll (NASDAQ:MLKN), a growth-oriented small-cap value company in the industrial and consumer sectors, today appointed Claire Spofford to its Board of Directors. An accomplished retail executive with more than 30 years of experience driving growth across leading consumer brands, Spofford brings deep expertise in omnichannel strategy, brand development, and operational excellence. She most recently served as President and Chief Executive Officer of J. Jill, where she helped transform the business, strengthened margins and refr

    1/16/26 4:05:00 PM ET
    $MLKN
    Office Equipment/Supplies/Services
    Consumer Discretionary

    $AGAE
    $ALT
    $AMS
    $AQMS
    Financials

    Live finance-specific insights

    View All

    Kingstone Reports Preliminary Record Fourth Quarter and Full Year 2025 Results

    Strongest Quarterly and Annual Results in Company History Q4 GAAP Net Combined Ratio in the range of 64% to 66% | Q4 Operating net income per diluted share1 in the range of $1.03 to $1.08 | Q4 ROE in the range of 49% to 51% Schedules Fourth Quarter Earnings Conference Call on Friday, March 6, at 8:30am ET KINGSTON, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kingstone Companies, Inc. (NASDAQ:KINS) (the "Company" or "Kingstone"), a Northeast regional property and casualty insurance holding company, today reported preliminary financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter Preliminary Results*Q4 2025Q4 2024Q4 ΔDirect Premiums Written1$83M$73M14%G

    2/4/26 8:00:00 AM ET
    $KINS
    Property-Casualty Insurers
    Finance

    Kingstone Declares Quarterly Dividend

    KINGSTON, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Kingstone Companies, Inc. (NASDAQ:KINS) (the "Company" or "Kingstone"), a Northeast regional property and casualty insurance holding company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.05 per share of common stock. The Company will pay the dividend on February 26, 2026, to stockholders of record at the close of business on February 11, 2026. About Kingstone Companies, Inc.Kingstone is a Northeast regional property and casualty insurance holding company whose principal operating subsidiary is Kingstone Insurance Company ("KICO"). KICO is a New York domiciled carrier writing business through ret

    1/30/26 8:30:00 AM ET
    $KINS
    Property-Casualty Insurers
    Finance

    H.B. Fuller Announces Quarterly Dividend

    H.B. Fuller Company (NYSE:FUL) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.2350 per share of common stock, payable on February 19, 2026 to shareholders of record at the close of business on February 5, 2026. H.B. Fuller has paid quarterly cash dividends on its common stock for 58 consecutive years. About H.B. Fuller As the largest pureplay adhesives company in the world, H.B. Fuller's (NYSE:FUL) innovative, functional coatings, adhesives and sealants enhance the quality, safety and performance of products people use every day. Founded in 1887, with 2025 revenue of $3.5 billion, our mission to Connect What Matters is brought to life by

    1/22/26 11:14:00 AM ET
    $FUL
    Home Furnishings
    Industrials

    $AGAE
    $ALT
    $AMS
    $AQMS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Investment Alert: Stock Acquired at Allied Gaming & Entertainment Inc. on Jul 4

    Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

    7/4/24 9:02:21 PM ET
    $AGAE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $AGAE
    $ALT
    $AMS
    $AQMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Allied Gaming & Entertainment Inc.

    SC 13D/A - Allied Gaming & Entertainment Inc. (0001708341) (Subject)

    12/11/24 2:35:54 PM ET
    $AGAE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care